The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.
The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images.
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.
The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens.